Congratulations to HELI 2011 alumnus Randy Brown, MD, PhD, DFASAM, on his promotion to Full Professor with tenure in the Department of Family Medicine and Community Health in the UW-Madison School of Medicine and Public Health! Dr. Brown is a researcher/clinician/teacher with many irons in ...
3. 在已切除的食管癌或胃食管连接部癌受试者中评价nivolumab与安慰剂相比的第1、2和3年生存率 目标入组人数:国际多中心试验:总体760人,中国25人; 入选标准: 排除标准: 参加医院和研究者:
研究药物:Nivolumab注射液,是百时美施贵宝公司(Bristol-Myers Squibb)在研的抗癌免疫药——抗PD-1单克隆抗体。 研究适应症:晚期食管鳞状细胞癌(ESCC)。 首次公示:2018-02-27 研究标题:nivolumab联合伊匹木单抗或化疗对比化疗一线治疗不可切除的晚期复发性或转移性...